A biopharmaceutical company specializing in products for cancer and supportive treatment.

, a biopharmaceutical company specializing in products for cancer and supportive treatment, announced today it offers signed an exclusive specialty distribution contract with BioScrip for its lead product, MuGard – – an FDA-accepted, ready-to-make use of mucoadhesive oral wound wash for the management of oral mucositis, a debilitating side-effect of radiotherapy and/or chemotherapy. is a national provider of specialty pharmacy and house care products and services that companions with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management delivery and solutions of cost-effective usage of prescription medications. Related StoriesNew antenna-like device makes breast cancer surgery less complicated for surgeonsOvarian cancer sufferers with a history of oral contraceptive use have better outcomesMeat-rich diet plan may increase kidney tumor risk As one of the largest, top-tier players in this space, BioScrip is well-established, focused and reliable on tailoring its applications to best match and meet product producers, supplier and payers and individuals’ pharmacy service needs, said Frank Jacobucci, VP of Advertising and Sales for Gain access to Pharmaceuticals, Inc.This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an editorially independent news program, is a program of the Kaiser Family Foundation, a nonpartisan healthcare policy research organization unaffiliated with Kaiser Permanente. Related StoriesVaccines – a needle-free long term? An interview with Thomas Dr and Johnston. In sufferers with RA, the disease fighting capability that is supposed to protect the body, instead episodes it for unknown factors. In a Phase I/IIa clinical trial recently explained in Proceedings of the National Academy of Sciences*, the UCSD researchers survey that a peptide called dnaJP1, taken orally for half a year by a group of patients with early RA, caused no unwanted effects and actually changed the actions of the immune system’s T cells, stopping them from attacking your body’s own tissues The new therapy happens to be in Phase II clinical trials with 160 RA individuals at UCSD, Johns Hopkins University, the Mayo Clinic, and Virginia Mason INFIRMARY in Seattle.